The stock price of Estrella Immunopharma Inc (NASDAQ: ESLA) has dropped by -11.21 compared to previous close of 1.16. Despite this, the company has seen a fall of -11.21% in its stock price over the last five trading days. businesswire.com reported 2025-03-05 that EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that CB Capital Partners has initiated coverage on the Company with a Buy rating and a price target of $14.00. “We appreciate CB Capital’s detailed evaluation of our proprietary ARTEMIS® T-cell platform and the progress we have.
Is It Worth Investing in Estrella Immunopharma Inc (NASDAQ: ESLA) Right Now?
The 36-month beta value for ESLA is also noteworthy at 0.42. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ESLA is 10.10M, and at present, short sellers hold a 0.21% of that float. The average trading volume of ESLA on May 12, 2025 was 88.44K shares.
ESLA’s Market Performance
ESLA stock saw an increase of -11.21% in the past week, with a monthly gain of 15.99% and a quarterly increase of -8.04%. The volatility ratio for the week is 14.67%, and the volatility levels for the last 30 days are 11.19% for Estrella Immunopharma Inc (ESLA). The simple moving average for the past 20 days is 3.11% for ESLA’s stock, with a -5.82% simple moving average for the past 200 days.
ESLA Trading at 6.59% from the 50-Day Moving Average
After a stumble in the market that brought ESLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.11% of loss for the given period.
Volatility was left at 11.19%, however, over the last 30 days, the volatility rate increased by 14.67%, as shares surge +13.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.29% upper at present.
During the last 5 trading sessions, ESLA fell by -11.21%, which changed the moving average for the period of 200-days by -33.55% in comparison to the 20-day moving average, which settled at $0.9990. In addition, Estrella Immunopharma Inc saw -14.17% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ESLA
The total capital return value is set at -11.81. Equity return is now at value -192.50, with -140.57 for asset returns.
Currently, EBITDA for the company is -7.31 million with net debt to EBITDA at 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.55.
Conclusion
In summary, Estrella Immunopharma Inc (ESLA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
